Corcept Therapeutics CORT Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's operating lease liabilities (total)?
- Corcept Therapeutics (CORT) reported operating lease liabilities (total) of $9.64M in Q1 2026.
- How has Corcept Therapeutics's operating lease liabilities (total) changed year-over-year?
- Corcept Therapeutics's operating lease liabilities (total) increased by 41.0% year-over-year, from $6.84M to $9.64M.
- What is the long-term trend for Corcept Therapeutics's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Corcept Therapeutics's operating lease liabilities (total) has grown at a 19.1% compound annual growth rate (CAGR), from $2.55M to $6.11M.
- What does operating lease liabilities (total) mean?
- The total value of future payments owed for operating leases.
- How do you interpret operating lease liabilities (total)?
- An increase indicates expansion of physical footprint or equipment usage, while a decrease may signal lease expirations or cost-cutting.
- How does operating lease liabilities (total) compare across companies?
- Standardized under modern accounting rules; used to assess off-balance-sheet financing risks.